Article Abstract

Extended follow-up on KEYNOTE-024 suggests significant survival benefit for pembrolizumab in patients with PD-L1 ≥50%, but unanswered questions remain

Authors: Jose M. Pacheco, Dexiang Gao, D. Ross Camidge

Abstract

Platinum-based doublets were the recommended systemic therapy for newly diagnosed patients with stage IV non-small cell lung cancer (NSCLC) for decades. Median overall survival (OS) for patients whose first treatment was these chemotherapy regimens was 8–12 months and 5-year OS was estimated at 2% (1-3).

Article Options

Download Citation